Published online Aug 6, 2022. doi: 10.12998/wjcc.v10.i22.7674
Peer-review started: March 16, 2022
First decision: April 11, 2022
Revised: May 5, 2022
Accepted: June 30, 2022
Article in press: June 30, 2022
Published online: August 6, 2022
Processing time: 127 Days and 20.4 Hours
Intestinal fibrosis is a serious complications of inflammatory bowel disease (IBD), but there is no effective drug treatment. Therefore, it is important to find drug treatments with fewer side effects.
To provide an objective basis for zedoary turmeric-trisomes in the treatment of IBD with intestinal fibrosis.
To investigate the use of network pharmacology and molecular docking technology in analyzing the effective components and mechanism of zedoary turmeric-trisomes in the treatment of IBD with intestinal fibrosis.
The Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform were used to extract the active components and action targets of zedoary turmeric-trisomes.
The protein-protein interaction network showed that the core therapeutic targets included JUN, MAPK14, CASP3, AR, and PTGS2. The GO enrichment analysis identified 759 items, and the KEGG enrichment analysis yielded 52 items. Molecular docking showed that the compound bonded with the target through hydrogen bond interactions and exhibited good docking activity.
This study identified the potential mechanism of action of zedoary turmeric-trisomes in the treatment of IBD using network pharmacology and molecular docking technology.
TCM has a potential mechanism in the treatment of IBD with intestinal fibrosis.